Related Experiment Video

Updated: Aug 15, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Therapeutic potential of iron chelators in cancer therapy

Des R Richardson1

  • 1The Iron Metabolism and Chelation Group, The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney, New South Wales, 2050 Australia.

Advances in Experimental Medicine and Biology
|February 8, 2003
PubMed

Insights

Chelators like deferoxamine (DFO) show promise in inhibiting aggressive tumor growth. Further research into chelators could yield novel anti-cancer agents and reveal insights into iron

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Cell Biology

Background:

  • Deferoxamine (DFO) demonstrates significant inhibition of aggressive tumor growth (neuroblastoma, leukemia).
  • DFO exhibits suboptimal pharmacokinetic properties, including poor membrane permeability and short serum half-life.
  • The thiosemicarbazone chelator, Triapine, is in Phase I clinical trials, reinforcing the therapeutic potential of chelators.

Purpose of the Study:

  • To explore the potential of chelators as anti-neoplastic agents.
  • To investigate the role of iron in cell cycle control within neoplastic cells.
  • To identify novel anti-cancer agents through the study of chelator effects on cancer cells.

Main Methods:

  • Review of existing literature on chelators and their anti-cancer effects.
  • Analysis of clinical trial data for chelator compounds.
  • Exploration of the biochemical mechanisms of iron's role in cell cycle regulation.

Main Results:

  • DFO effectively inhibits the growth of aggressive tumors.
  • Triapine's progression to Phase I clinical trials validates the therapeutic promise of chelators.
  • Chelator studies offer insights into iron's function in cell cycle control.

Conclusions:

  • Chelators represent a promising class of anti-neoplastic agents.
  • Overcoming DFO's limitations could lead to more effective cancer therapies.
  • Further research on chelators and iron metabolism is crucial for advancing cancer treatment and understanding cell cycle regulation.

More Related Videos

Biofunctionalization of Magnetic Nanomaterials06:40

Biofunctionalization of Magnetic Nanomaterials

Published on: July 16, 2020

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...